The Excelsoft Technologies share price forecast for the next 3 years points to a scenario range of Rs 86 to Rs 140 by 2030, driven by rising global demand for digital assessment and learning management platforms and sector tailwinds.

The Ester Industries share price forecast for the next 3 years points to a scenario range of Rs 97 to Rs 160 by 2030, driven by rising demand for specialty polyester films from packaging and electrical insulation applications and sector tailwinds.

Avenue Supermarts (DMart) vs Trent growth compares value retail supermarket chain with disciplined, profitable expansion against fashion retail chain with rapid value-format store growth to see which retail has better growth.

The Eurotex Industries and Exports share price forecast for the next 3 years points to a scenario range of Rs 15 to Rs 24 by 2030, driven by any recovery in cotton yarn demand and steady wind power generation cash flows and sector tailwinds.

The Excel Industries share price forecast for the next 3 years points to a scenario range of Rs 990 to Rs 1,630 by 2030, driven by rising demand for biofertilisers and specialty agrochemicals as sustainable farming practices gain adoption and sector tailwinds.

IndiGo vs SpiceJet financial health compares market-leading, consistently profitable airline with sustained fleet expansion against smaller airline working through financial recovery and fleet constraints to see which airlines has better financial health.

The Finkurve Financial Services share price forecast for the next 3 years points to a scenario range of Rs 70 to Rs 115 by 2030, driven by rising digital lending adoption and expansion of its fintech lending platform and sector tailwinds.

Torrent Pharmaceuticals vs Zydus Lifesciences growth compares domestic branded formulations leadership with select international expansion against diversified generics, consumer wellness and specialty portfolio to see which pharma has better growth.

SBI Cards vs Bajaj Finance business model compares concentrated credit card issuance leveraging SBI’s banking distribution against diversified consumer lending across personal loans, durables and credit cards to see which nbfc has better business model.

Sun Pharma vs Dr Reddy’s Laboratories specialty vs generics focus compares specialty drug development alongside a large generics base against biosimilars and generics-led growth strategy to see which pharma has better specialty vs generics focus.